These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW; Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P; Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875 [TBL] [Abstract][Full Text] [Related]
11. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365 [TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Hernandez GD; Solinsky CM; Mack WJ; Kono N; Rodgers KE; Wu CY; Mollo AR; Lopez CM; Pawluczyk S; Bauer G; Matthews D; Shi Y; Law M; Rogawski MA; Schneider LS; Brinton RD Alzheimers Dement (N Y); 2020; 6(1):e12107. PubMed ID: 33344752 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389 [TBL] [Abstract][Full Text] [Related]
19. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Nygaard HB; Wagner AF; Bowen GS; Good SP; MacAvoy MG; Strittmatter KA; Kaufman AC; Rosenberg BJ; Sekine-Konno T; Varma P; Chen K; Koleske AJ; Reiman EM; Strittmatter SM; van Dyck CH Alzheimers Res Ther; 2015; 7(1):35. PubMed ID: 25874001 [TBL] [Abstract][Full Text] [Related]
20. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease. van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]